JP2005528348A - Ppar活性を変調するチアゾールおよびオキサゾール誘導体 - Google Patents

Ppar活性を変調するチアゾールおよびオキサゾール誘導体 Download PDF

Info

Publication number
JP2005528348A
JP2005528348A JP2003572567A JP2003572567A JP2005528348A JP 2005528348 A JP2005528348 A JP 2005528348A JP 2003572567 A JP2003572567 A JP 2003572567A JP 2003572567 A JP2003572567 A JP 2003572567A JP 2005528348 A JP2005528348 A JP 2005528348A
Authority
JP
Japan
Prior art keywords
methyl
phenyl
compound
trifluoromethyl
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2003572567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528348A5 (enExample
Inventor
シュー−ミン・チェン
ノエ・ワーノ・エラスガ
ゲアリ・フレデリック・フィルゼン
アンドルー・ジョージ・ガイアー
チタセ・リー
ブハラト・カリダス・トリヴェディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2005528348A publication Critical patent/JP2005528348A/ja
Publication of JP2005528348A5 publication Critical patent/JP2005528348A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2003572567A 2002-03-07 2003-02-24 Ppar活性を変調するチアゾールおよびオキサゾール誘導体 Abandoned JP2005528348A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07
PCT/IB2003/000708 WO2003074050A1 (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate ppar activity

Publications (2)

Publication Number Publication Date
JP2005528348A true JP2005528348A (ja) 2005-09-22
JP2005528348A5 JP2005528348A5 (enExample) 2006-04-13

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003572567A Abandoned JP2005528348A (ja) 2002-03-07 2003-02-24 Ppar活性を変調するチアゾールおよびオキサゾール誘導体

Country Status (29)

Country Link
US (1) US20030207924A1 (enExample)
EP (1) EP1482935B1 (enExample)
JP (1) JP2005528348A (enExample)
KR (1) KR20040091693A (enExample)
AP (1) AP2004003124A0 (enExample)
AR (1) AR038881A1 (enExample)
AT (1) ATE405260T1 (enExample)
AU (1) AU2003206059A1 (enExample)
BR (1) BR0308277A (enExample)
CA (1) CA2478520A1 (enExample)
CO (1) CO5601012A2 (enExample)
DE (1) DE60323060D1 (enExample)
EA (1) EA200400943A1 (enExample)
EC (1) ECSP045285A (enExample)
ES (1) ES2310650T3 (enExample)
HN (1) HN2003000090A (enExample)
IS (1) IS7377A (enExample)
MA (1) MA27181A1 (enExample)
MX (1) MXPA04007564A (enExample)
NO (1) NO20044242L (enExample)
OA (1) OA12780A (enExample)
PA (1) PA8567801A1 (enExample)
PE (1) PE20030989A1 (enExample)
PL (1) PL372969A1 (enExample)
TN (1) TNSN04168A1 (enExample)
TW (1) TW200305403A (enExample)
UY (1) UY27695A1 (enExample)
WO (1) WO2003074050A1 (enExample)
ZA (1) ZA200406068B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528987A (ja) * 2003-05-19 2006-12-28 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
WO2007102515A1 (ja) * 2006-03-07 2007-09-13 Astellas Pharma Inc. フェニルチアゾール誘導体
US7939519B2 (en) 2003-05-19 2011-05-10 Novartis Ag Immunosuppresant compounds and compositions
JP2013525267A (ja) * 2010-02-25 2013-06-20 エスエヌユー アール&ディービー ファウンデーション ペルオキシソーム増殖剤活性化受容体リガンドのセレナゾール誘導体、その製造方法及びその化合物の用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1737809B1 (en) * 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
JP5191744B2 (ja) * 2005-02-25 2013-05-08 ソウル ナショナル ユニバーシティー インダストリー ファンデーション ペルオキシソーム増殖子活性化受容体デルタリガンドのチアゾール誘導体及びその製造方法
US7982050B2 (en) * 2005-05-07 2011-07-19 Seoul National University Industry Foundation Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
EP1916234B1 (en) * 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
EA201101085A1 (ru) 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルgpr40調節因子
AU2008338963A1 (en) * 2007-12-13 2009-06-25 Sri International PPAR-delta ligands and methods of their use
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
RU2174121C2 (ru) * 1996-08-19 2001-09-27 Джапан Тобакко Инк. Производные пропионовой кислоты и фармацевтическая композиция на их основе
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ グループ リミテッド hPPARアルファアゴニストとしての置換オキサゾールおよびチアゾール
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
DE60216094T2 (de) * 2001-06-07 2007-06-06 Eli Lilly And Co., Indianapolis Modulatoren der peroxisom-proliferator-aktivierten rezeptoren (ppar)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528987A (ja) * 2003-05-19 2006-12-28 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
US7939519B2 (en) 2003-05-19 2011-05-10 Novartis Ag Immunosuppresant compounds and compositions
WO2007102515A1 (ja) * 2006-03-07 2007-09-13 Astellas Pharma Inc. フェニルチアゾール誘導体
JP2013525267A (ja) * 2010-02-25 2013-06-20 エスエヌユー アール&ディービー ファウンデーション ペルオキシソーム増殖剤活性化受容体リガンドのセレナゾール誘導体、その製造方法及びその化合物の用途

Also Published As

Publication number Publication date
MXPA04007564A (es) 2004-11-10
CO5601012A2 (es) 2006-01-31
ECSP045285A (es) 2004-10-26
KR20040091693A (ko) 2004-10-28
CA2478520A1 (en) 2003-09-12
MA27181A1 (fr) 2005-01-03
US20030207924A1 (en) 2003-11-06
ATE405260T1 (de) 2008-09-15
OA12780A (en) 2006-07-07
NO20044242L (no) 2004-10-06
IS7377A (is) 2004-07-29
EP1482935B1 (en) 2008-08-20
AR038881A1 (es) 2005-02-02
PA8567801A1 (es) 2003-11-12
AP2004003124A0 (en) 2004-09-30
ES2310650T3 (es) 2009-01-16
AU2003206059A1 (en) 2003-09-16
UY27695A1 (es) 2003-10-31
TW200305403A (en) 2003-11-01
PE20030989A1 (es) 2003-11-29
PL372969A1 (en) 2005-08-08
EP1482935A1 (en) 2004-12-08
WO2003074050A1 (en) 2003-09-12
BR0308277A (pt) 2004-12-28
ZA200406068B (en) 2005-09-06
HN2003000090A (es) 2004-05-05
TNSN04168A1 (fr) 2007-03-12
DE60323060D1 (de) 2008-10-02
EA200400943A1 (ru) 2005-02-24

Similar Documents

Publication Publication Date Title
US20030207924A1 (en) Compounds that modulate PPAR activity and methods of preparation
JP3490704B2 (ja) チアゾールおよびオキサゾール誘導体ならびにそれらの医薬的使用
US6833380B2 (en) Compounds that modulate PPAR activity and methods of preparation
JP2005527509A (ja) Ppar活性を調節する、置換チアゾールおよびオキサゾール
CZ20031737A3 (cs) Thiazolové deriváty
RS82904A (sr) Jedinjenja koja moduliraju delovanje ppar i postupci za njihovo dobijanje
SK1962001A3 (en) Substituted oxazoles and thiazoles derivatives as hppar gamma and hppar alpha activators
MXPA04007177A (es) Alimentacion para animales baja en fosforo y metodo para hacer la misma.
MXPA01001419A (en) SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060224

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20080903